French drug maker Sanofi reported Friday a higher profit in its first quarter, while net sales were hurt mainly by weak results in Diabetes unit and Venezuela. Excluding Venezuela. Aggregate Group sales increased 3 percent at constant exchange rates. Looking ahead, the company continues to expect 2016 business earnings per share to be broadly stable at CER.